James Neal joins XOMA Ltd., to aid in building biodefense programs

James R. Neal has joined XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, as vice president of business development.

Neal will oversee the business development strategy of XOMA and lead a team in executing key licensing initiatives to build and support XOMA's biodefense programs and its proprietary therapeutic pipeline.

Neal will also aid in marketing the company's antibody technologies and assess commercial opportunities while developing product candidates commercially.

"We continue to increase the strength of our management team in order to capitalize on the value of our antibody technologies, product candidates and expertise," Steven Engle, chairman and chief executive officer of XOMA, said. "Jim is a seasoned executive with extensive experience in forging successful partnerships with pharmaceutical companies and government institutions. This experience will be key for our product candidates like XOMA 052, new antibody collaborations and our biodefense programs."

Neal brings over 25 years experience in forming and maximizing valuable business and technology collaborations globally to XOMA as well as knowledge of bringing novel products and technologies to market.

Neal holds a bachelor of science in biology and a master of science in genetics and plant breeding from the University of Manitoba, Canada, and an executive MBA from Washington University in St. Louis, Missouri.